Target intelligence / Profile preview

RERG antisense RNA 1 (non-protein coding) (RERG-AS1)

Target: RERG-AS1
Molecular classification: Antisense long non-coding RNA (antisense lncRNA), Non-protein coding RNA, Enhancer RNA (functionally similar to antisense eRNAs in mechanisms)

Overview

RERG antisense RNA 1 (RERG-AS1) is an antisense long non-coding RNA transcribed from the RERG gene locus. Antisense lncRNAs regulate gene expression by various mechanisms, including recruitment of chromatin-modifying enzymes, DNA methylation, RNA-RNA duplex formation, or modulation of mRNA stability and translation. The broader class of antisense lncRNAs plays key roles in oncogenic and tumor suppressor pathways across multiple cancer types. Although lncRNAs like RERG-AS1 are being studied for their role in cancer cell proliferation, invasion, and gene regulation, RERG-AS1 itself is not currently established as a direct therapeutic target, biomarker, or has known drug interactions.

Other names: RERG-AS1RERG antisense RNA 1 (non-protein coding)

Biological functions

Regulation of gene expression (typically post-transcriptional or epigenetic)Chromatin remodeling and DNA methylation via recruitment of enzymes (extrapolated from similar antisense lncRNAs)Potential involvement in cell proliferation, invasion, and cancer-related pathways (based on the roles of similar antisense lncRNAs)

Disease associations

Cancer (Antisense lncRNAs are reported to function as oncogenes or tumor suppressors in various cancer types; specific roles for RERG-AS1 in cancer have been mentioned in academic catalogs and research tools, but published mechanistic data are limited currently)

Beyond the preview

Go deeper on RERG antisense RNA 1 (non-protein coding) (RERG-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RERG antisense RNA 1 (non-protein coding) (RERG-AS1).

Explore the full profile